Lupin has received final USFDA approval to market a generic version of Novartis’ inhalation product Tobi, which is used to treat cystic fibrosis, in the American market. The drug is indicated for management of cystic fibrosis patients. As per IMS MAT December 2016 sales data, Tobramycin inhalation solution had sales of USD 133.6 million in the US market.
Company Profile : Lupin Ltd
Leave a Reply